Form 8-K - Current report:
SEC Accession No. 0001213900-25-058035
Filing Date
2025-06-26
Accepted
2025-06-26 07:01:09
Documents
14
Period of Report
2025-06-26
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0247000-8k_aldeyra.htm   iXBRL 8-K 26569
2 ALDEYRA THERAPEUTICS, INC. PRESS RELEASE DATED JUNE 26, 2025 ea024700001ex99-1_aldeyra.htm EX-99.1 17044
3 GRAPHIC ex99-1_001.jpg GRAPHIC 12037
  Complete submission text file 0001213900-25-058035.txt   232427

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE aldx-20250626.xsd EX-101.SCH 3011
5 XBRL LABEL FILE aldx-20250626_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE aldx-20250626_pre.xml EX-101.PRE 22356
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0247000-8k_aldeyra_htm.xml XML 3688
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 251075035
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)